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It has been firmly established that cisplatin-based 
chemotherapy in the neoadjuvant setting prior to radical 
cystectomy improves overall survival in patients with 
muscle invasive bladder cancer (1). This study demonstrates 
and argues that improvement in overall survival with 
neoadjuvant chemotherapy (NACT) is not only related 
to a complete clinical response (pT0N0), but also to any 
pathologic downstaging, whether complete or a partial 
response from the initial clinical stage at diagnosis (2). 
Both the Retrospective International Study of Cancer of 
the Urothelial Tract (RISC) and National Cancer Database 
(NCDB) were queried in this study to identify a cohort 
of patients that had complete pathologic response or 
downstaging with NACT. Multivariable Cox proportional 
hazard models were used to demonstrate the effect of 
downstaging and complete pathologic response on overall 
survival in the data set. The analysis ultimately found that 
any pathologic response is associated with improved overall 
survival, but a couple caveats should be noted. 
First, data compiled for the study includes patients 
from the NCDB with T2-T4N0M0 disease, which may 
make it difficult to accurately and consistently determine 
clinical staging given that T3/T4 staging relies on imaging 
interpretation and bimanual examination. Both of which 
are highly operator dependent and a bimanual examination 
under anesthesia is rarely performed and well-documented 
in the pre-operative setting. Nonetheless, despite the 
limitation in accurately determining pre-operative clinical 
staging, where such clinical staging is indeed available, the 
results and conclusions should generally remain the same—
that any pathological response and downstaging is a marker 
for improved survival. 
Another limitation to note in this accumulated patient 
population is that clinical downstaging and complete 
response may not only be the result of NACT but also as 
result of a well-performed TURBT. As mentioned in the 
study, one of the confounding factors during the work-up 
for bladder cancer is that transurethral resection alone can 
clinically downstage patients. As reported, in this article, 
Shariat et al. reported a rate of 22% clinical downstaging 
for patient undergoing cystectomy alone (3). Brant et al. 
demonstrated that clinical downstaging may be impacted 
by TURBT alone about 38% of the time, but still showed 
that patients receiving NACT showed a greater response to 
treatment (4). A well performed, TURBT without NACT 
may address small volume cT2 disease, but will not account 
for residual T3/4 or nodal involvement. The authors 
control for this in their study.
Ultimately, this study makes the point that overall 
survival is correlated by the different levels of response to 
NACT, which should then be considered as a valid primary 
or secondary outcome in clinical trials with promising novel 
agents that have shown success in early phase trials. Based 
on the results of this study, we can cautiously infer that the 
initial success of novel agents such as immune checkpoint 
inhibitors (PD-1 and PD-L1 inhibitors for urothelial 
carcinoma) demonstrating preliminary results of disease 
regression should lead to favorable outcomes and increased 
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overall survival after appropriate follow up. Of note, based 
on this study 33–35% of patients achieved pathologic down 
staging and complete pathologic response was achieved 
by 15–20% of the patients based on the cohorts from the 
two databases. In a recent neoadjuvant clinical trial where 
patients received pembrolizumab followed by cystectomy, 
42% of patients experienced a complete pathologic response 
and 54% of patients experienced clinical downstaging (5). 
Another combined neoadjuvant chemo-immunotherapy 
trial showed an unprecedented 48% complete pathologic 
response and 65% clinical downstaging to combination 
cisplatin, gemcitabine and pembrolizumab (6). Both 
studies classified pathologic downstaging as defined by 
any pathology T2 or less in the clinical trial involving 
pembrolizumab including patients with complete response, 
whereas this study defined downstaging as any patient who 
experienced a response to NACT regardless of staging. 
Perhaps this new measure of outcome would lead to an even 
higher “downstaging” effect, which will hopefully correlate 
to improved survival. Long-term follow-up from these two 
clinical trials will help answer this and potentially validate 
this study by Martini et al. 
The authors further argue, that given this improvement 
in overall survival based on any degree of pathologic 
downstaging, perhaps we can measure success differently in 
clinical trials going forward. As clinical trials for immune 
checkpoint inhibitors are completed, pathological response 
should correlate to longitudinal improvement in overall 
survival. However, only after longer follow up will we be 
able to confirm that immune checkpoint inhibitors can 
lead to longer overall survival and utilize any pathologic 
downstaging as a functional measure of improvement of 
long-term survival benefit. There is still the possibility 
that the overall survival curve may not exactly produce the 
same survivability curves as NACT. The differences in the 
biology and pharmacology between immune checkpoint 
inhibitors and NACT can change the survivability 
curve despite initial results of disease regression. To 
illustrate these differences, some studies have shown that 
pembrolizumab or atezolizumab can prolong survival and 
have efficacy in the adjuvant setting after failing cisplatin 
based chemotherapy (7,8). Patients receiving PD-1 
inhibitors have shown evidence of developing adaptive 
mechanism for immune resistance (5). If patients experience 
disease progression after receiving a neoadjuvant checkpoint 
inhibitor, the biology of this advanced urothelial carcinoma 
may be different compared to bladder cancer that is naïve 
to a checkpoint inhibitor. It is unclear exactly what the 
longitudinal survival curves will look like in patients who 
received these PD-1 inhibitors. Thus, the comparative 
analysis looking at cancer free survival and overall survival 
with patients receiving PD-1 and PD-L1 inhibitors and 
patients receiving NACT will be needed. 
In the end, despite convincing evidence that any 
pathological response leads to improved overall survival, 
in the setting of NACT and cystectomy, making a similar 
conclusion with novel therapies is not absolute. Although 
demonstrating disease regression or complete response 
shows promise in terms of overall measurable survival, 
confirmation of efficacy is yet to be definitively determined 
until enough time passes for appropriate follow up of these 
patients.
Acknowledgments
Funding: None.
Footnote
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/tau.2019.12.28). The authors have no 
conflicts of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. 
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and 
the original work is properly cited (including links to both 
the formal publication through the relevant DOI and the 
license). See: https://creativecommons.org/licenses/by-nc-
nd/4.0/.
References
1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant 
chemotherapy plus cystectomy compared with cystectomy 
alone for locally advanced bladder cancer. N Engl J Med 
2003;349:859-66.
833Translational Andrology and Urology, Vol 9, No 2 April 2020
  Transl Androl Urol 2020;9(2):831-833 | http://dx.doi.org/10.21037/tau.2019.12.28© Translational Andrology and Urology. All rights reserved.
2. Martini A, Jia R, Ferket BS, et al. Tumor downstaging 
as an intermediate endpoint to assess the activity of 
neoadjuvant systemic therapy in patients with muscle-
invasive bladder cancer. Cancer 2019;125:3155-63.
3. Shariat SF, Palapattu GS, Karakiewicz PI, et al. 
Discrepancy between clinical and pathologic stage: 
impact on prognosis after radical cystectomy. Eur Urol 
2007;51:137-49; discussion 149-51.
4. Brant A, Kates M, Chappidi MR, et al. Pathologic response 
in patients receiving neoadjuvant chemotherapy for 
muscle-invasive bladder cancer: Is therapeutic effect owing 
to chemotherapy or TURBT? Urol Oncol 2017;35:34.
e17-34.e25.
5. Necchi A, Anichini A, Raggi D, et al. Pembrolizumab 
as Neoadjuvant Therapy Before Radical Cystectomy 
in Patients With Muscle-Invasive Urothelial Bladder 
Carcinoma (PURE-01): An Open-Label, Single-Arm, 
Phase II Study. J Clin Oncol 2018:36. doi: 10.1200/
JCO.18.01148.
6. Hoimes CJ, Albany C, Hoffman-Censits J, et al. A phase 
Ib/II study of neoadjuvant pembrolizumab (pembro) and 
chemotherapy for locally advanced urothelial cancer (UC). 
Ann Oncol 2018;29:mdy424.039.
7. Narayan V, Kahlmeyer A, Dahm P, et al. Pembrolizumab 
monotherapy versus chemotherapy for treatment of 
advanced urothelial carcinoma with disease progression 
during or following platinum-containing chemotherapy. 
A Cochrane Rapid Review. Cochrane Database Syst Rev 
2018;7:CD012838.
8. Powles T, Duran I, van der Heijden MS, et al. 
Atezolizumab versus chemotherapy in patients with 
platinum-treated locally advanced or metastatic urothelial 
carcinoma (IMvigor211): a multicentre, open-label, phase 
3 randomised controlled trial. Lancet 2018;391:748-57.
Cite this article as: Tachibana I, Kaimakliotis HZ. Tumor 
downstaging in muscle invasive bladder cancer with neoadjuvant 
systemic therapy—does it lead to prolonged survival? Transl 
Androl Urol 2020;9(2):831-833. doi: 10.21037/tau.2019.12.28
